Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Allergan buys migraine drug partner MAP for $884mm

Executive Summary

Allergan Inc. is buying publicly traded MAP Pharmaceuticals Inc. (using formulation and inhalation technologies to develop neurological drug candidates) for $884mm in cash, or $25 per share (a 57% premium). The acquisition is Allergan’s second-largest to date, coming in behind the company’s 2005 takeover of aesthetics firm Inamed for $3.1bn.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
      • Site Specific
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register